Rheumatology Medical News about Ankylosing spondylitis, Adalimumab, HRQOL

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis
Arthritis Research & Therapy, 08/21/09

van der Heijde DM et al. – In this study adalimumab significantly improved disease activity, patient-reported physical function, and health-related quality-of-life (HRQOL) in patients with ankylosing spondylitis (AS); these benefits were maintained over 3 years of treatment.

Methods

An evaluation of 3-year impact of adalimumab on patient-reported physical function and HRQOL outcomes in pts with active AS
ATLAS is an ongoing 5-yr study that included an initial 24-wk randomized period, followed by open-label extension treatment with adalimumab
Clinical and HRQOL data collected for up to 3 yrs from ATLAS were used for these analyses
Pts were randomized to receive adalimumab 40 mg or placebo by sc injection every other wk
Physical function was assessed by BASFI and SF-36, Health Survey PCS, and Physical Function subscale scores
HRQOL was assessed using the AS Quality of Life (ASQOL) questionnaire
Disease activity was assessed by BASDAI

Results

315 pts; 91% participated in an open-label adalimumab treatment extension and 82% provided 3-yr outcome data
During the 24-wk double-blind phase, adalimumab-treated pts experienced:
- Improvement in the BASDAI, BASFI, ASQOL, and both the SF-36 PCS, and Physical Function subscale scores
- No improvement in the SF-36 Mental Component Summary score, and Mental Health subscale scores
Mean changes from baseline through 3 yrs of adalimumab treatment were significant for the BASDAI, BASFI, SF-36 PCS, and Physical Function
Comparable results were observed for other SF-36 scores and for the ASQOL

<< Previous
Short- and long-term effects of anti-CD20 treatment on B cell...

Next >>
Work disability in ankylosing spondylitis: Differences among...